VP Clinical Pharmacology/Translational Medicine
Chimerix, Inc.
Dr. Naderer is currently the Vice President of Clinical Pharmacology and Translational Medicine, a position he has held for the past 9 years. Prior to joining Chimerix, he served as Medicine Development Leader and Senior Scientific Director, within the Infectious Disease Development Unit at GlaxoSmithKline for 15 years. During his tenure at GSK, Dr. Naderer was involved with the approval of 2 antiretroviral medications and served as the European Federation of Pharmaceutical Industries and Associations (EFPIA) Coordinator for the Innovative Medicines Initiative (IMI)-funded New Drugs for Bad Bugs Clinical Trial Consortium (COMBACTE) in Europe. Most recently at Chimerix, he was the Principal Investigator on Biomedical Advanced Research and Development Authority (BARDA) contract HHSO100201100013C that was used to support the development and FDA approval of TEMBEXA®. TEMBEXA® is now included in the strategic national stockpile as a medical countermeasure in the event of a Smallpox outbreak. Dr. Naderer earned a B.S. in Nutrition and Medical Dietetics and his PharmD at the University of Illinois at Chicago, after which he completed a General Practice Residency in Cooperstown, NY and an Infectious Diseases Specialty Residency at the University of Texas Health Science Center in San Antonio. Upon completing his clinical residency training, he pursued a joint academic/industry Drug Development Fellowship at the UNC and GlaxoWellcome